Jefferies Financial Group Upgrades Aligos Therapeutics (NASDAQ:ALGS) to “Strong-Buy”

Aligos Therapeutics (NASDAQ:ALGS) was upgraded by investment analysts at Jefferies Financial Group to a “strong-buy” rating in a research note issued to investors on Friday, Zacks reports.

ALGS has been the topic of several other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aligos Therapeutics in a research report on Friday, May 29th. Weiss Ratings downgraded shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. HC Wainwright restated a “buy” rating on shares of Aligos Therapeutics in a research report on Monday, August 10th. Finally, Lake Street Capital initiated coverage on shares of Aligos Therapeutics in a research report on Thursday, May 28th. They issued a “buy” rating and a $45.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.50.

Aligos Therapeutics Price Performance

NASDAQ ALGS opened at $5.51 on Friday. The business has a 50 day moving average price of $5.75 and a 200 day moving average price of $6.13. The company has a market capitalization of $34.38 million, a P/E ratio of -0.75 and a beta of 2.34. Aligos Therapeutics has a 1-year low of $3.98 and a 1-year high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.95. The company had revenue of $27.78 million for the quarter, compared to the consensus estimate of $24.68 million. Aligos Therapeutics had a negative return on equity of 160.72% and a negative net margin of 241.01%. On average, research analysts expect that Aligos Therapeutics will post -6.81 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in shares of Aligos Therapeutics by 1,652.8% during the 1st quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock worth $1,707,000 after purchasing an additional 216,646 shares during the last quarter. SummitTX Capital L.P. lifted its stake in shares of Aligos Therapeutics by 6.7% during the first quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after buying an additional 9,375 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Aligos Therapeutics by 17.6% during the first quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock valued at $746,000 after buying an additional 15,006 shares during the period. Finally, Rockefeller Capital Management L.P. boosted its position in Aligos Therapeutics by 900.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after acquiring an additional 9,000 shares during the last quarter. Institutional investors and hedge funds own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for chronic liver diseases, viral infections and related conditions. The company uses its research platforms to discover and advance small-molecule therapies designed to address significant unmet medical needs.

Its development programs have included treatments for chronic hepatitis B, metabolic dysfunction-associated steatohepatitis (MASH) and viral respiratory diseases. The company’s hepatitis B pipeline has included capsid assembly modulators, while its MASH efforts have included therapies intended to improve liver health and reduce disease progression.